课题基金 / 基金详情

Unacylated Ghrelin to Improve FuncTioning in PAD: the GIFT Trial

Unacylated Ghrelin to Improve FuncTioning in PAD: the GIFT Trial
非酰化 Ghrelin 改善 PAD 功能:GIFT 试验
批准号:
9927974
负责人:
Mary McGrae McDermott
金额:
$20.22万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-05-15 至 2023-12-31

项目摘要

项目成果

Mary McGrae McDermott的其他基金

相似基金

相关文献

中文摘要
翻译
未酰化胃饥饿素改善PAD的功能:GIFT试验
英文摘要
Unacylated Ghrelin to Improve FuncTioning in PAD: the GIFT Trial Our work and that of others shows that patients with lower extremity peripheral artery disease (PAD) have greater functional impairment, faster functional decline, and higher rates of mobility loss compared to people without PAD. In patients with PAD, ischemia results in calf muscle injury that includes myofiber loss and calf muscle mitochondrial dysfunction. Therapies to regenerate calf skeletal muscle cells, improve mitochondrial function, and increase calf muscle capillary density may improve functioning and prevent mobility loss in people with PAD. Yet few effective therapies currently exist for patients with PAD. This pilot study will investigate the therapeutic potential of unacylated ghrelin to promote capillary growth, increase calf muscle perfusion, and reverse PAD-related skeletal muscle abnormalities, thereby improving PAD-related functional impairment. Ghrelin is a peptide and hormone that circulates in acylated and unacylated forms. Unacylated ghrelin promotes skeletal muscle cell regeneration, improves mitochondrial function, and increases muscle capillary density. Unlike acylated ghrelin, unacylated ghrelin does not increase appetite, or cause insulin resistance. The proposed GIFT Trial will provide preliminary data to test our hypothesis that unacylated ghrelin improves walking performance and prevents mobility loss in older patients with PAD. We further hypothesize that the favorable effect of unacylated ghrelin will be mediated by increased myofiber regeneration, increased muscle capillary density, and improved muscle mitochondria function. If our preliminary data support our hypotheses, results will be used to design a large randomized trial of unacylated ghrelin therapy, in subsequent study, to improve functioning and prevent mobility loss in older people with PAD. We will conduct a pilot randomized trial in 30 participants age 60 and older with PAD, to gather preliminary evidence about whether daily subcutaneously administered unacylated improves the six-minute walk distance (primary outcome), maximal treadmill walking distance (secondary outcome), and calf muscle perfusion (secondary outcome), compared to placebo. We will also perform calf muscle biopsies at baseline and follow up to determine whether unacylated ghrelin increases Type 1 skeletal muscle myofibers, satellite cell number, capillary density, and succinate dehydrogenase (SDH) mitochondrial activity in calf skeletal muscle, compared to placebo. If our hypotheses are correct, results will be used to design a large, definitive randomized trial of unacylated ghrelin to improve lower extremity functioning and prevent mobility loss in the large and growing number of older people who are disabled by PAD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Far Red Light to Improve Functioning in PAD: the LIGHT PAD Trial
  • 批准号:
    10572758
  • 项目类别:
  • 资助金额:
    $26.76万
  • 财政年份:
    2023
  • 负责人:
    Mary McGrae McDermott
  • 依托单位:
Response to Exercise and Nitric Oxide in PAD: the RESIST PAD Trial
  • 批准号:
    10656845
  • 项目类别:
  • 资助金额:
    $74.92万
  • 财政年份:
    2023
  • 负责人:
    Mary McGrae McDermott
  • 依托单位:
ENhancing exercise with LIGHT to improve functioning in PAD: the ENLIGHTEN PAD Trial
  • 批准号:
    10645929
  • 项目类别:
  • 资助金额:
    $26.75万
  • 财政年份:
    2023
  • 负责人:
    Mary McGrae McDermott
  • 依托单位:
BEET root juice to reverse functional impairment in PAD: The BEET PAD Trial
  • 批准号:
    10440812
  • 项目类别:
  • 资助金额:
    $73.98万
  • 财政年份:
    2022
  • 负责人:
    Mary McGrae McDermott
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: